Home / Pharmaceuticals / Anticoagulants Market By Drug Class (Novel Oral Anticoagulants (NOACs), Vitamin K Antagonists, Heparins & Low Molecular Weight Heparins (LMWH), Antiplatelet Agents, Thrombolytic Agents, Direct Thrombin Inhibitors), By Application (Atrial Fibrillation & Heart Attacks, Strokes, Deep Vein Thrombosis (DVT), Pulmonary Embolism) - Growth, Future Prospects, Competitive Analysis, 2018 - 2026

Anticoagulants Market By Drug Class (Novel Oral Anticoagulants (NOACs), Vitamin K Antagonists, Heparins & Low Molecular Weight Heparins (LMWH), Antiplatelet Agents, Thrombolytic Agents, Direct Thrombin Inhibitors), By Application (Atrial Fibrillation & Heart Attacks, Strokes, Deep Vein Thrombosis (DVT), Pulmonary Embolism) - Growth, Future Prospects, Competitive Analysis, 2018 - 2026

Published: Mar 2019 | Report Code: 59614-03-19

The global anticoagulants market was valued at US$ 33,150.7 Mn in 2017 and expected to grow at compound annual growth rate (CAGR) of 6.6% during the forecast period from 2018 to 2026. Anticoagulants are prescribed to patients who are at higher risk of clot formation in the blood and reduce the risk of serious conditions such as strokes and heart attacks. Anticoagulants are also given to treat pulmonary embolism, deep vein thrombosis (DVT), atrial fibrillation and other cardiovascular diseases. Thus, increasing prevalence of cardiovascular diseases, especially DVT, atrial fibrillation and peripheral artery diseases is a major growth factor assisting the market. Launch of several novel oral anticoagulants (NOACs) with improved properties in the last decade has completely changed the market scenario over the years. Warfarin a vitamin K antagonists was the most preferred anticoagulants earlier as it was efficient in inhibiting the vitamin K recycling. However, use of warfarin had certain limitations such as continuous monitoring of international normalized ratio (INR) i.e. drug levels and drug-food & drug-drug interactions, acting as the drawbacks for the market.

NOACs are also referred as non-vitamin K antagonist oral anticoagulants, consisting for coagulation factors Xa inhibitors, factor IIa inhibitors and direct thrombin inhibitors which has faster onset of drug and lowered side effects compared to other drugs. The currently marketed NOACs include babigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Lixiana/Savaysa) and betrixaban (Bevyxxa). Xarelto by Bayer/ Janssen Pharmaceuticals and Eliquis by Pfizer/ Bristol-Myers Squibb are the most prescribed NOACs globally owing to impressing efficacy rate in the trials, lower side-effects such as uncontrollable bleeding and the ability of the drugs to treat multiple indications, provide an upper hand in the market. Bevyxxa by Portola Pharmaceuticals was the latest addition in the market, getting U.S. Food and Drug Administration (FDA) approval in June 2017 and launched in January 2018 for prophylaxis of venous thromboembolism (VTE). This will further drive the market for anticoagulants market.

Market Synopsis 

Anticoagulants Market

Get a sample copy for more information

"Novel Oral Anticoagulants Will Drive the Anticoagulants Market During the Forecast Period"  

In 2017, NOACs held the largest share of more than 50% of the overall anticoagulants market. The segment is projected to exhibit fastest growth rate during the forecast period as NOACs provides higher advantage over vitamin K antagonist in terms of safety, lower side effects such as bleeding episodes, decreased need for continuous dosage monitoring and availability of anticoagulant reversal agents. Higher prices of NOACs as compared to other drug segment also leads to the growth of the market.

Anticoagulants Market

Get a sample copy for more information

Historical & Forecast Period

This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

Anticoagulants market report furnishes quantitative analysis along with its latest market trends. The market is segmented based on drug class, application and geography.

ATTRIBUTE DETAILS
Research Period  2016-2026
Base Year 2017
Forecast Period  2018-2026
Historical Year  2016
Unit  USD Million
Segmentation

 By Drug Class (2016–2026; US$ Mn)
 • Novel Oral Anticoagulants (NOACs)
 • Vitamin K Antagonists
 • Heparins & Low Molecular Weight Heparins (LMWH)
 • Antiplatelet Agents
 • Thrombolytic Agents
 • Direct Thrombin Inhibitors

 By Application (2016–2026; US$ Mn)
 • Atrial Fibrillation & Heart Attacks
 • Strokes
 • Deep Vein Thrombosis (DVT)
 • Pulmonary Embolism

 Geography Segment (2016–2026; US$ Mn)
 • North America (U.S., Canada)
 • Europe (U.K., Germany, Rest of Europe)
 • Asia Pacific (China, Japan, Rest of APAC)
 • Latin America (Brazil, Mexico, Rest of Latin America)
 • Middle East and Africa (GCC, Rest of Middle East and Africa)

Market is studied in order to understand the current dynamics and future trends in the global anticoagulants market. The study includes market size and forecast for all considered segments presented in the report for the period from 2016 to 2026, along with respective compound annual growth rate (CAGRs) for the forecast period from 2018 to 2026, considering 2017 as the base year. The key players currently engaged in anticoagulants market include Bayer AG, Janssen Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Pfizer, Inc., Daiichi Sankyo Company Limited, and Portola Pharmaceuticals, Inc. among others.


Anticoagulants Market

Get a sample copy for more information

Key questions answered in this report

  • How the global anticoagulants market will perform during the forecast period from 2018 to 2026?
  • What are the latest trends in the anticoagulants market and valuable opportunities for key players?
  • Who are the leading players in the global anticoagulants market?
  • Which is the leading and fastest region in the global anticoagulants market?
  • What are drivers and restrains governing the global anticoagulants market?

Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global Anticoagulants Market Portraiture
2.2. Global Anticoagulants Market, by Drug Class, 2017 (US$ Mn)
2.3. Global Anticoagulants Market, by Application, 2017 (US$ Mn)
2.4. Global Anticoagulants Market, by Geography, 2017 (US$ Mn)

Chapter 3. Anticoagulants: Market Dynamics and Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Anticoagulants Market, by Key Players, 2017

Chapter 4. Global Anticoagulants Market, by Drug Class, 2016-2026 (US$ Mn)
4.1. Overview
4.2. Novel Oral Anticoagulants (NOACs)
4.3. Vitamin K Antagonists
4.4. Heparins & Low Molecular Weight Heparins (LMWH)
4.5. Antiplatelet Agents
4.6. Thrombolytic Agents
4.7. Direct Thrombin Inhibitors
4.8. Pipeline Analysis (Forecast for Phase III drugs till 2026)

Chapter 5. Global Anticoagulants Market, by Application Type, 2016-2026 (US$ Mn)
5.1. Overview
5.2. Atrial Fibrillation & Heart Attacks
5.3. Strokes
5.4. Deep Vein Thrombosis (DVT)
5.5. Pulmonary Embolism

Chapter 6. Global Anticoagulants Market, by Geography, 2016 – 2026 (US$ Mn)
6.1. North America Anticoagulants Market Analysis, 2016 – 2026
6.1.1. North America Anticoagulants Market, by Drug Class, 2016 - 2026 (US$ Mn)
6.1.2. North America Anticoagulants Market, by Application, 2016 - 2026 (US$ Mn)
6.1.3. North America Anticoagulants Market, by Country, 2016 – 2026 (US$ Mn)
6.1.3.1. U.S.
6.1.3.2. Canada
6.2. Europe Anticoagulants Market Analysis, 2016 – 2026
6.2.1. Europe Anticoagulants Market, by Drug Class, 2016 - 2026 (US$ Mn)
6.2.2. Europe Anticoagulants Market, by Application, 2016 - 2026 (US$ Mn)
6.2.3. Europe Anticoagulants Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.2.3.1. U.K.
6.2.3.2. Germany
6.2.3.3. Rest of Europe
6.3. Asia Pacific Anticoagulants Market Analysis, 2016 – 2026
6.3.1. Asia Pacific Anticoagulants Market, by Drug Class, 2016 - 2026 (US$ Mn)
6.3.2. Asia Pacific Anticoagulants Market, by Application, 2016 - 2026 (US$ Mn)
6.3.3. Asia Pacific Anticoagulants Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.3.3.1. China
6.3.3.2. Japan
6.3.3.3. Rest of Asia Pacific
6.4. Latin America Anticoagulants Market Analysis, 2016 – 2026
6.4.1. Latin America Anticoagulants Market, by Drug Class, 2016 - 2026 (US$ Mn)
6.4.2. Latin America Anticoagulants Market, by Application, 2016 - 2026 (US$ Mn)
6.4.3. Latin America Anticoagulants Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.4.3.1. Brazil
6.4.3.2. Mexico
6.4.3.3. Rest of Latin America
6.5. Middle East & Africa Anticoagulants Market, 2016 – 2026
6.5.1. Middle East & Africa Anticoagulants Market, by Drug Class, 2016 - 2026 (US$ Mn)
6.5.2. Middle East & Africa Anticoagulants Market, by Application, 2016 - 2026 (US$ Mn)
6.5.3. Middle East & Africa Anticoagulants Market, by Region, 2016 – 2026 (US$ Mn)
6.5.3.1. GCC
6.5.3.2. Rest of Middle East & Africa

Chapter 7. Company Profiles
7.1. Boehringer Ingelheim Internation GmbH
7.1.1. Business Description
7.1.2. Financial Information (Subject to Data Availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. Bayer AG
7.3. Johnson & Johnson, Inc.
7.4. Bristol-Myers Squibb Company
7.5. Pfizer, Inc.
7.6. Daiichi-Sankyo Company Limited
7.7. Portola Pharmaceuticals, Inc.
7.8. Sanofi S.A.
7.9. Aspen Holdings
7.10. GlaxoSmithKline Plc

Note: Modification in the list of company profiles or scope of the study can be incorporated on request.

FIG 1. Anticoagulants Market: Research Methodology
FIG 2. Anticoagulants: Market Segmentation
FIG 3. Global Anticoagulants Market, by Drug Class, 2017 (US$ Mn)
FIG 4. Global Anticoagulants Market, by Application Type, 2017 (US$ Mn)
FIG 5. Global Anticoagulants Market, by Geography, 2017 (US$ Mn)
FIG 6. Attractive Investment Proposition, by Geography, 2017
FIG 7. Competitive Analysis: Global Anticoagulants Market, by Key Players, 2017
FIG 8. Global Novel Oral Anticoagulants (NOACs) Market, 2016-2026 (US$ Mn)
FIG 9. Global Vitamin K Antagonist Drug Class in Anticoagulants Market, 2016-2026 (US$ Mn)
FIG 10. Global Heparins & Low Molecular Weight Heparins (LMWH) Drug Class in Anticoagulants Market, 2016-2026 (US$ Mn)
FIG 11. Global Antiplatelet Agents Drug Class in Anticoagulants Market, 2016-2026 (US$ Mn)
FIG 12. Global Thrombolytic Agents Drug Class in Anticoagulants Market, 2016-2026 (US$ Mn)
FIG 13. Global Direct Thrombin Inhibitors Drug Class in Anticoagulants Market, 2016-2026 (US$ Mn)
FIG 14. Global Anticoagulant Market for Atrial Fibrillation & Heart Attacks, 2016-2026(US$ Mn)
FIG 15. Global Anticoagulant Market for Strokes, 2016-2026(US$ Mn)
FIG 16. Global Anticoagulant Market for Deep Vein Thrombosis (DVT), 2016-2026(US$ Mn)
FIG 17. Global Anticoagulant Market for Pulmonary Embolism, 2016-2026(US$ Mn)
FIG 18. U.S. Anticoagulant Market, 2016-2026 (US$ Mn)
FIG 19. Canada Anticoagulant Market, 2016-2026 (US$ Mn)
FIG 20. U.K. Anticoagulant Market, 2016-2026 (US$ Mn)
FIG 21. Germany Anticoagulant Market, 2016-2026 (US$ Mn)
FIG 22. Rest of Europe Anticoagulant Market, 2016-2026 (US$ Mn)
FIG 23. China Anticoagulant Market, 2016-2026 (US$ Mn)
FIG 24. Japan Anticoagulant Market, 2016-2026 (US$ Mn)
FIG 25. Rest of Asia Pacific Anticoagulant Market, 2016-2026 (US$ Mn)
FIG 26. Brazil Anticoagulant Market, 2016-2026 (US$ Mn)
FIG 27. Mexico Anticoagulant Market, 2016-2026 (US$ Mn)
FIG 28. Rest of Latin America Anticoagulant Market, 2016-2026 (US$ Mn)
FIG 29. GCC Anticoagulant Market, 2016-2026 (US$ Mn)
FIG 30. Rest of Middle East & Africa Anticoagulant Market, 2016-2026 (US$ Mn)

TABLE 1 Global Anticoagulant Market Portraiture
TABLE 2 Global Anticoagulant Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 3 Global Anticoagulant Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 4 Global Anticoagulant Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 5 North America Anticoagulant Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 6 North America Anticoagulant Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 7 North America Anticoagulant Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 8 Europe Anticoagulant Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 9 Europe Anticoagulant Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 10 Europe Anticoagulant Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 11 Asia Pacific Anticoagulant Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 12 Asia Pacific Anticoagulant Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 13 Asia Pacific Anticoagulant Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 14 Latin America Anticoagulant Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 15 Latin America Anticoagulant Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 16 Latin America Anticoagulant Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 17 Middle East & Africa Anticoagulant Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 18 Middle East & Africa Anticoagulant Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 19 Middle East & Africa Anticoagulant Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 20 Boehringer Ingelheim Internation GmbH: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 Bayer AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Johnson & Johnson, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Bristol-Myers Squibb Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 Daiichi-Sankyo Company Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Portola Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 Sanofi S.A.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 Aspen Holdings: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 GlaxoSmithKline Plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Our Clients